United Overseas Bank Fourth-Quarter Net Rises on Non-Interest Income
By P.R. Venkat
United Overseas Bank's fourth-quarter net profit rose thanks to higher non-interest income and fee-related revenues.
Profit for the quarter came in at 1.40 billion Singapore dollars (US$1.04 billion), up 22% on-year, with total income posting a 2% increase, to S$3.41 billion, the bank said Thursday.
The board has recommended a final dividend of 85 Singapore cents a share that takes the total dividend payment payout of S$1.70 a share.
The company said that net interest income was down 6% on year, to S$2.40 billion, due to lower net interest margin. However, net fee income grew 17% during the fourth quarter, to S$569 million, as the bank's wealth management and credit-card fees rose.
Non-interest income rose to S$438.0 million from S$$285.0 million on higher treasury income and strong performance from trading and liquidity management activities.
"Global economic outlook remains uncertain in the near term, but Southeast Asia continues to be a bright spot," the bank's Chief Executive Wee Ee Cheong said.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
February 21, 2024 18:49 ET (23:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks